Lexston Life Sciences Corp. (TSE:LEXT)
:LEXT
Want to see TSE:LEXT full AI Analyst Report?
LEXT Stock Chart & Stats
C$0.10
<C$0.01(11.11%)
At close: 4:00 PM EST
C$0.10
<C$0.01(11.11%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.34
Previous CloseN/A
Volume1.00M
Average Volume (3M)40.70K
Market Cap
C$1.00M
Enterprise ValueC$126.42K
Total Cash (Recent Filing)C$278.52K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.26
Next Earnings
Sep 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding25,093,304
10 Day Avg. Volume77,591
30 Day Avg. Volume40,703
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)13.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero reported debt load is a durable structural strength: it reduces insolvency and interest-cost risk, preserves strategic optionality for financing growth or R&D via equity, and gives management flexibility to execute strategic moves without immediate refinancing pressure.
Improving Free Cash Flow TrendAn improving free cash flow trend, even from a negative base, signals early operational leverage or cost control that can extend runway and lower near-term financing needs. If sustained, this trend helps the company move toward self-funding and reduces dilution risk over months.
Prior Revenue And Positive Gross Profit HistoryHistorical ability to generate revenue and positive gross profit demonstrates the company has had product-market traction in the past, providing a tangible basis for re-monetization strategies and indicating existing assets or capabilities that could be re-levered.
Bears Say
Zero Recent RevenueSustained absence of revenue across multiple recent years is a fundamental red flag: it means the core business has failed to produce recurring sales, forcing reliance on external capital and raising the risk that operational scale and customer channels remain unproven over the medium term.
Persistent Operating Cash BurnConsistent negative operating cash flow (~-$1.0M TTM) erodes cash reserves and creates a structural financing need: over months this raises dilution and refinancing risk, constrains investments in product or commercialization, and limits the firm's ability to self-sustain growth initiatives.
Consistent Losses And Negative ROERepeated net losses and a deeply negative ROE indicate the company is not compounding shareholder capital. Over the medium term this undermines investor returns, limits retained-earnings financing, and suggests the business model or execution has not yet produced sustainable profitability.
Lexston Life Sciences Corp. News
LEXT FAQ
What was Lexston Life Sciences Corp.’s price range in the past 12 months?
Lexston Life Sciences Corp. lowest stock price was C$0.04 and its highest was C$0.34 in the past 12 months.
What is Lexston Life Sciences Corp.’s market cap?
Lexston Life Sciences Corp.’s market cap is C$1.00M.
When is Lexston Life Sciences Corp.’s upcoming earnings report date?
Lexston Life Sciences Corp.’s upcoming earnings report date is Sep 21, 2026 which is in 105 days.
How were Lexston Life Sciences Corp.’s earnings last quarter?
Lexston Life Sciences Corp. released its earnings results on Apr 03, 2026. The company reported -C$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.016.
Is Lexston Life Sciences Corp. overvalued?
According to Wall Street analysts Lexston Life Sciences Corp.’s price is currently Overvalued.
Does Lexston Life Sciences Corp. pay dividends?
Lexston Life Sciences Corp. does not currently pay dividends.
What is Lexston Life Sciences Corp.’s EPS estimate?
Lexston Life Sciences Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lexston Life Sciences Corp. have?
Lexston Life Sciences Corp. has 25,093,304 shares outstanding.
What happened to Lexston Life Sciences Corp.’s price movement after its last earnings report?
Lexston Life Sciences Corp. reported an EPS of -C$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lexston Life Sciences Corp.?
Currently, no hedge funds are holding shares in TSE:LEXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lexston Life Sciences Corp.
Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing and validating methods for standardized manufacturing of plant derived psychedelics in the field of mental health and wellness. The company is based in Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---